Publication:
Effect of EARLY administration of DEXamethasone in patients with COVID-19 pneumonia without acute hypoxemic respiratory failure and risk of development of acute respiratory distress syndrome (EARLY-DEX COVID-19): study protocol for a randomized controlled trial.

Loading...
Thumbnail Image

Date

2022-09-15

Authors

Franco-Moreno, Anabel
Acedo-Gutiérrez, María Soledad
Martín, Nicolás Labrador-San
Hernández-Blanco, Clara
Rodríguez-Olleros, Celia
Ibáñez-Estéllez, Fátima
Suárez-Simón, Ana
Balado-Rico, Mateo
Romero-Paternina, Ana Rocío
Alonso-Menchén, David

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

Corticosteroids are one of the few drugs that have shown a reduction in mortality in coronavirus disease 2019 (COVID-19). In the RECOVERY trial, the use of dexamethasone reduced 28-day mortality compared to standard care in hospitalized patients with suspected or confirmed COVID-19 requiring supplemental oxygen or invasive mechanical ventilation. Evidence has shown that 30% of COVID-19 patients with mild symptoms at presentation will progress to acute respiratory distress syndrome (ARDS), particularly patients in whom laboratory inflammatory biomarkers associated with COVID-19 disease progression are detected. We postulated that dexamethasone treatment in hospitalized patients with COVID-19 pneumonia without additional oxygen requirements and at risk of progressing to severe disease might lead to a decrease in the development of ARDS and thereby reduce death. This is a multicenter, randomized, controlled, parallel, open-label trial testing dexamethasone in 252 adult patients with COVID-19 pneumonia who do not require supplementary oxygen on admission but are at risk factors for the development of ARDS. Risk for the development of ARDS is defined as levels of lactate dehydrogenase > 245 U/L, C-reactive protein > 100 mg/L, and lymphocyte count of  245 U/L, C-reactive protein > 100 mg/L, and lymphocyte count of  100 mg/L, and lymphocyte count of  If our hypothesis is correct, the results of this study will provide additional insights into the management and progression of this specific subpopulation of patients with COVID-19 pneumonia without additional oxygen requirements and at risk of progressing to severe disease. ClinicalTrials.gov NCT04836780. Registered on 8 April 2021 as EARLY-DEX COVID-19.

Description

MeSH Terms

Adrenal Cortex Hormones
Adult
C-Reactive Protein
COVID-19
Dexamethasone
Humans
Lactate Dehydrogenases
Multicenter Studies as Topic
Oxygen
Pneumonia
Randomized Controlled Trials as Topic
Respiratory Distress Syndrome
Respiratory Insufficiency
COVID-19 Drug Treatment

DeCS Terms

CIE Terms

Keywords

Adult respiratory distress syndrome, COVID-19 pneumonia, Corticosteroids, Dexamethasone, Inflammatory biological markers, Laboratory markers, Mortality, Randomized controlled trial

Citation